TG Therapeutics receives FDA approval for Briumvi for relapsing MS

The FDA approved Briumvi, a CD20-directed cytolytic antibody, for the treatment of relapsing forms of multiple sclerosis, or MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, according to a post to the agency’s website. Reference Link